BioXcel Therapeutics, Inc. (BTAI)
| Market Cap | 338.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -112.03M |
| Shares Out | 27.99M |
| EPS (ttm) | -4.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,182,269 |
| Open | 12.47 |
| Previous Close | 12.06 |
| Day's Range | 11.91 - 12.60 |
| 52-Week Range | 8.80 - 36.49 |
| Beta | 1.30 |
| Analysts | Buy |
| Price Target | 58.75 (+385.1%) |
| Earnings Date | Aug 9, 2022 |
About BTAI
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutic... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is 58.75, which is an increase of 385.14% from the latest price.
News
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
NEW HAVEN, Conn., June 07, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transf...
2 Stocks Under $20 That Could Double Your Money
These two companies have gotten quite the haircuts in recent months.
BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference
NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfo...
Why Shares of BioXcel Therapeutics Climbed 25.2% This Week
With the company's launch of its first marketed drug on the horizon, investors showed some excitement.
BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights
Received FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults
Why BioXcel Therapeutics Shares Went Up 12.9% This Week
The company is stepping up its efforts to expand the label uses of its lead therapy.
BioXcel Therapeutics to Present at Three Upcoming Investor Conferences
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfo...
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation i...
Top-line data for TRANQUILITY II anticipated in Q4 2022/early Q1 2023
2 Small-Cap Stocks With Monster Upsides, According to Wall Street
Sometimes analysts are on the spot, and other times, not so much.
BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence (AI) approaches to identify...
BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need
BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority
Investment will support upcoming U.S. commercial launch activities of IGALMI™ and further clinical pipeline development
4 Top Stock Trades for Thursday: MSFT, TWTR, BTAI, PXD
Microsoft, Twitter, BioXcel Therapeutics and Pioneer Natural Resources were our top stock trades for Thursday. Here's the trade now.
Why BioXcel Therapeutics Stock Is Surging Today
BioXcel Therapeutics Inc (NASDAQ: BTAI) shares are trading higher Wednesday after the company announced that the U.S. Food and Drug Administration approved IGALMI (dexmedetomidine) sublingual film for t...
BioXcel says the FDA approved its therapy for adults with schizophrenia or bipolar disorder
Shares of BioXcel Therapeutics Inc. BTAI, -2.98% jumped 14.6% in premarket trading on Wednesday after the company said the Food and Drug Administration approved Igalmi, a sublingual film used to treat a...
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agita...
First and only FDA-approved orally dissolving sublingual film for mild, moderate or severe agitation in patients with schizophrenia or bipolar I or II disorder 1
Why Shares of BioXcel Therapeutics Shot Up 25.4% This Week
Investors may be anticipating a positive review by the FDA of the company's lead drug candidate.
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
Ready to launch BXCL501 upon approval as Company nears April 5, 2022 PDUFA action date
BioXcel Therapeutics to Present at the Barclays Global Healthcare Conference
NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfo...
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...
BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivot...
BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo
BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2...
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts
BioXcel Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
NEW HAVEN, Conn., Feb. 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...
BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer
NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...
BioXcel Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
NEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transfor...